NEW YORK (360Dx) – HTG Molecular disclosed in a filing with the US Securities and Exchange Commission that it has entered into a statement of work with Qiagen Manchester, a UK-based subsidiary of Qiagen, pursuant to a previously announced master assay development, commercialization, and manufacturing agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.